NASDAQ:ASND
Ascendis Pharma A/S Stock News
$137.20
-3.90 (-2.76%)
At Close: May 03, 2024
Ascendis Pharma A/S (NASDAQ:ASND) Receives Overweight Rating from Cantor Fitzgerald
06:12am, Saturday, 20'th Nov 2021 Dakota Financial News
Ascendis Pharma A/S (NASDAQ:ASND)s stock had its overweight rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research note issued on Thursday, Zacks.com reports. ASND has been the topic of several other research reports. Bank of America downgraded Ascendis Pharma A/S from a buy rating to a neutral rating and raised their price []
Ascendis'' Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks
12:40pm, Friday, 19'th Nov 2021 Benzinga
Ascendis Pharma A/S (NASDAQ: ASND ) announced topline results from Week 84 of its Phase 2 PaTH Forward Trial of its TransCon PTH candidate hypoparathyroidism (HP). Hypoparathyroidism is a condition in which the body produces abnormally low levels of PTH, the key to regulating and maintaining a balance of two calcium and phosphorus. TransCon PTH is an investigational once-daily Full story available on Benzinga.com
Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $190.00 at SVB Leerink
06:32am, Friday, 19'th Nov 2021 Transcript Daily
Ascendis Pharma A/S (NASDAQ:ASND) had its price objective upped by SVB Leerink from $182.00 to $190.00 in a research note released on Monday morning, Analyst Price Targets reports. The brokerage currently has an outperform rating on the biotechnology companys stock. ASND has been the subject of several other research reports. JPMorgan Chase & Co. increased []
Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward Trial Demonstrating that TransCon™ PTH Provided Durable Benefit and Was Well-Tolerated in Adults with Hypoparathyroidism
09:42pm, Thursday, 18'th Nov 2021 GlobeNewswire Inc.
–– 58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial.
Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward Trial Demonstrating that TransCon PTH Provided Durable Benefit and Was Well-Tolerated in Adults with Hypoparathyroidism
09:42pm, Thursday, 18'th Nov 2021 Intrado Digital Media
58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial.
Analysts Expect Ascendis Pharma A/S (NASDAQ:ASND) Will Post Earnings of -$2.78 Per Share
05:52pm, Thursday, 18'th Nov 2021 Transcript Daily
Wall Street analysts forecast that Ascendis Pharma A/S (NASDAQ:ASND) will post earnings of ($2.78) per share for the current quarter, Zacks reports. Four analysts have provided estimates for Ascendis Pharma A/Ss earnings. The highest EPS estimate is ($1.93) and the lowest is ($3.71). Ascendis Pharma A/S reported earnings of ($3.15) per share during the same []
Ascendis Pharma A/S to Participate in the Evercore ISI 4th Annual HealthCONx Conference
09:05pm, Wednesday, 17'th Nov 2021 GlobeNewswire Inc.
COPENHAGEN, Denmark, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the Evercore ISI 4th Annual HealthCONx Confe
Ascendis Pharma A/S to Participate in the Evercore ISI 4th Annual HealthCONx Conference
09:05pm, Wednesday, 17'th Nov 2021 Intrado Digital Media
COPENHAGEN, Denmark, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the Evercore ISI 4th Annual HealthCONx Conference. Company executives will participate in a virtual fireside chat hosted by Evercore ISI.
Baker Bros. Advisors Lp Buys Ascendis Pharma A/S, Pacific Biosciences of California Inc, ...
12:38am, Wednesday, 17'th Nov 2021 GuruFocus
Related Stocks: ASND , PACB , TVTX , LEGN , KYMR , BLUE , DICE , SRZN , TCRX , TNGX , AMYT , LIFE , APLS , ADCT , PTGX , ASMB , ISEE , SBTX ,
Zacks: Brokerages Expect Ascendis Pharma A/S (NASDAQ:ASND) Will Announce Earnings of -$2.78 Per Share
03:40pm, Tuesday, 16'th Nov 2021 Dakota Financial News
Wall Street brokerages expect Ascendis Pharma A/S (NASDAQ:ASND) to report ($2.78) earnings per share for the current quarter, Zacks reports. Four analysts have issued estimates for Ascendis Pharma A/Ss earnings, with estimates ranging from ($3.71) to ($1.93). Ascendis Pharma A/S reported earnings per share of ($3.15) during the same quarter last year, which would indicate []
Ascendis (ASND) Gets Positive CHMP Opinion for GHD Drug Filing
04:00pm, Monday, 15'th Nov 2021 Zacks Investment Research
Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.
Ascendis Pharma A/S' (ASND) CEO Jan Mikkelsen on Q3 2021 Results - Earnings Call Transcript
12:13am, Thursday, 11'th Nov 2021
Ascendis Pharma A/S' (ASND) CEO Jan Mikkelsen on Q3 2021 Results - Earnings Call Transcript
COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment fo
– Late-breaking oral presentation will feature a comprehensive review of 58-week results from the company's Phase 2 PaTH Forward Trial –
Ascendis Pharma A/S Announces Share Repurchase Program
04:01pm, Wednesday, 29'th Sep 2021
COPENHAGEN, Denmark, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new